<?xml version="1.0" encoding="utf-8"?>
    
            

    
        



    <rss xmlns:content="http://purl.org/rss/1.0/modules/content/"  version="2.0">
        <channel>
            <title>Recently Published About HMA</title>
            <link>https://www.hma.eu//rss/recently-published-about-hma.html</link>
            <description>New contents from the website www.hma.eu. Category: Recently Published About HMA</description>
            <language>en</language>
            <copyright>Heads of Medicines Agencies</copyright>
            <pubDate>Mon, 13 Jul 2026 10:53:23 +0200</pubDate>
            
                <item>
                    <title><![CDATA[Introduction/Overview/Mandate]]></title>
                    <description><![CDATA[Terms of Reference/Mandate for the HMA Working Group on Pharmaceuticals in the Environment | pdf]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups/pie/pie.html#c7871</link>
                    <guid>https://www.hma.eu//about-hma/working-groups/pie/pie.html#c7871</guid>
                    <pubDate>Thu, 01 Jan 1970 01:00:00 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[Members and Representatives]]></title>
                    <description><![CDATA[The WG PiE is composed of representatives from national competent authorities (NCA’s) in AT, BE, CZ, DE, DK, ES, FI, FR, HR, NL, PT, SE, IT and EMA. WG PiE is currently chaired by Swedish Medical Products Agency (SMPA) with an election every three years.Meeting cycle: four meetings per year, including one physical meeting.Chair: Stefan Berggren, MPA, SESecretariat: Katharina Högdin, MPA, SESecretariat: 2nd member od Secretariat pendingMeeting cycle: four meetings per year, including one physical meeting.]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups/pie/pie.html#c7872</link>
                    <guid>https://www.hma.eu//about-hma/working-groups/pie/pie.html#c7872</guid>
                    <pubDate>Thu, 01 Jan 1970 01:00:00 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[CTCG News and Events]]></title>
                    <description><![CDATA[FAST-EU Pilot Demonstrates Europe's Capacity for Accelerated and Coordinated Clinical Trial Authorisation
Three months into the pilot, 15 multinational clinical trials are progressing under accelerated timelines, with the first three procedures completed within the 70-day target
The Clinical Trials Coordination Group (CTCG) operating under the umbrella of the Heads of Medicines Agencies (HMA), and MedEthics EU under the auspices of the European Commission, today publish the first interim results of the FAST-EU pilot initiative (Facilitating and Accelerating Strategic Clinical Trials in the EU).
The pilot already applies the new accelerated procedure and mechanisms proposed by the Commission in the revision of the Clinical Trial Regulation in the Biotech Act, and thus serves as an early operational testbed for the revised clinical trial authorisation procedure. This new procedure aims to deliver a shorter, simpler and more predictable approval process. It does so while maintaining the highest standards of participant safety and data quality. 
Background
Launched in February 2026, FAST-EU is a voluntary pilot implemented within the framework of Regulation (EU) No 536/2014 (Clinical Trials Regulation, CTR). It aims to accelerate the coordinated assessment and authorisation of multinational clinical trial applications across Member States, while fully maintaining scientific, safety and ethical standards. FAST-EU operates entirely within the Clinical Trials Information System (CTIS) and does not alter the legal rights or obligations of any party.
The pilot serves as a practical proof of concept for the European Commission's proposal for an EU Biotech Act, demonstrating the feasibility of the streamlined and time-bound authorisation model for clinical trials. It is also a testimony of the strong commitment of Member States and sponsors to its implementation.
Strong Demand from Sponsors
In the first three months of operation, the FAST-EU Coordination Office received 68 Expressions of Interest from sponsors across Europe and internationally. Of these, 15 procedures were selected for inclusion in the pilot - three in February, four in March, four in April, and four in May 2026. The volume of applications exceeded the originally planned pilot capacity of two procedures per month, reflecting both the strong interest from the sponsor community and the willingness of Member States to step up to the challenge of increased demand.
The 15 selected trials cover a broad range of therapeutic areas, including oncology and haematology (7 trials), neurology and neurodegenerative diseases (2), cardiovascular and pulmonary vascular disease (2), and immunology and inflammatory disease (2). Trials span all development phases, from Phase I to Phase III, and involve on average 7.33 participating Member States per procedure, with individual trials involving up to 14 Member States. 
First Completed Procedures Confirm Feasibility of 70-Day Target
Three procedures have been completed to date, all meeting or closely approximating the 70-calendar-day target set by FAST-EU*1. These results demonstrate that the 70-day timeline is operationally achievable across a diverse range of trial types, indication areas, and Member State constellations. 
Participating Member States and RMS Distribution
Twenty-six Member States and EEA countries are participating in FAST-EU. Reporting Member State distribution reflects the pan-European character of the initiative. RMS roles completed or ongoing include Italy, Denmark, the Netherlands, Germany (PEI), Finland, Poland, Sweden, Spain, Belgium, Norway, and the Czech Republic - with Romania, Hungary, Austria, and Portugal planned for upcoming procedures.
Relevance for the EU Biotech Act
he FAST-EU pilot was conceived in part as a proof of concept for the accelerated and coordinated clinical trial authorisation model anticipated under the EU Biotech Act. The pilot's timeline architecture - parallel validation, timelines based on full weeks, a single consolidated RFI round for Part I and a 70-day overall target - closely mirrors the  European Commission proposal for a revised authorisation procedure in the Biotech Act, aimed at creating a more competitive, agile and predictable European regulatory environment for clinical research.The interim results support the conclusion that this model is operationally feasible within the existing CTR framework, even where certain functionalities such timelines and separate validation processes are not yet supported by CTIS infrastructure. 
Next Steps
Ongoing evaluation will include qualitative findings from structured interviews with Reporting Member States on coordination effort, application of the reliance principle, and challenges for integration of Ethics Committees. A full pilot report will be published upon conclusion.
Sponsors wishing to submit an Expression of Interest for the FAST-EU pilot may contact the FAST-EU Coordination Office at FAST-EU@hma.eu. Further information is available in the FAST-EU External Guidance for Sponsors (Version 1.2, April 2026), published on the CTCG website.
The Clinical Trials Coordination Group (CTCG) is a standing working group of the Heads of Medicines Agencies (HMA), responsible for the operational implementation of the EU Clinical Trials Regulation. MedEthics EU under the auspices of the European Commission is the corresponding coordination body for Ethics Committees across the EU/EEA. 
1^ For one trial a deviation of one day related to the Easter public holiday period was noted and documented.


Article 11 workaround – MSCs intended to receive Part I only initial submission 
Sponsors are encouraged to include all MSCs where the clinical trial is planned to be conducted in the initial application to promote alignment of the Part I dossier (see Article 11 of the Clinical Trials Regulation on Part I only initial submission). 
However, in current CTIS sponsors cannot proceed with trial applications (substantial modifications, additional MSCs) if MSCs remain as Part I only.
A new Article 11 workaround (see the guidance published on the website on March 27 2026) applies from April 27 2026. It allows sponsors to include MSCs intended to receive Part I only by submitting Part II placeholders. The procedure also involves Part I only MSCs in reviews of subsequent SM Part I applications.
The trial is neither allowed to start nor recruit participants in MSCs where only placeholder data/documents Part II were submitted before actual Part II data/documents have been submitted and authorised.
For more background, see CTAG (Clinical Trials Coordination and Advisory Group) minutes to be published by the European Commission Mar 27 2026 from the Nov 27-28 2025 meeting at the Register of Commission expert groups and other similar entities, where CTAG is listed as group X03839
CTCG has organised a webinar on 15 April 2026, with more than 500 participants joining the meeting, during which it was explained how to apply this new approach, how to monitor these trials and where to find the supporting documents. It also provide insights into the new approach where to upload translated versions of patient facing documents into CTIS.
Meeting schedule for 2026
DateDate of the weekLocation09-10 February 2026Monday & Tuesday EMA09-10 March 2026Monday & Tuesday Virtual 13-14 April 2026Monday & TuesdayEMA20 May 2026WednesdayVirtual03-04 June 2026Tuesday & Wednesday Cyprus 08-09 July 2026 Wednesday & Thursday Virtual 09-10 September Wednesday & Thursday EMA08-09 October 2026Thursday & Friday Virtual 19-20 November 2026Thursday & FridayIreland 09-10 December 2026Wednesday & Thursday Virtual

]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7039</link>
                    <guid>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7039</guid>
                    <pubDate>Mon, 22 Jul 2024 15:26:00 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[CTCG Key documents list]]></title>
                    <description><![CDATA[TEMPLATES 
COVER LETTERS and RFI RESPONSE
CTCG provides the following templates, to be used in different situations:
Initial Applications
Initial application cover letter | docx - Version 7, June 2026Part II placeholder document Article 11 workaround | pdf - Version 1.1, May 2026 (see Article 11 guidance for sponsor below)
Substantial Modification (SM)
Cover letter | docx - Version 4, March 2026Modification description | docx - Version 3, March 2026
Request of Further Information
RFI Response List of Changes to the Application | docx - Version 2, June 2025 
CTIS Guidance
Best practice guide naming of documents in CTIS | pdf - Version 3, March 2026
Sponsor guidance on Article 11 workaround
Guidance for sponsor on Article 11 workaround | pdf - Version 1, March 2026MSC intended to receive part I only initial submission - procedure applies from April 27 2026New rules translations of patient facing documents and new template recruitment  - CTIS Info Day 17 June 2026Article 11 workaround: Concept and Supporting Documents - Webinar 15 April 2026
Transitional Trials
CTCG Best Practice Guide for sponsors who have missed the transition timeline | pdf - Version 1, January 2025CTCG Best Practice Guide for sponsors of multinational clinical trials with different Part I document versions approved in different Member States under the Directive 2001/20/EC that will transition to the Regulation (EU) No. 536/2014 | pdf - Version 5, June 2024Annex I - Cover letter template | docx - Version 5, June 2024Annex II - Fees for transitional trials in MSs | pdf - Version 1, June 2024
First SM: document requirements after transition
CTCG Best Practice Guide to sponsors updating the application dossier Part I after CTR transition | pdf  - Version 1, June 2024Annex I Cover letter template First SM after Transition | docx - Version 3, November 2025Annex II Modification Description template First SM after transition  | docx - Version 2, June 2024Annex III First SM Part II after transition | pdf - Version 1, April 2024
GUIDANCE
Frequently asked questions related to Clinical trials submitted under the Regulation EU 536/2014
FAQ document | pdf - Version 2, April 2026
Guide for Change of Trial Sponsor
Guide for Change of Trial Sponsor | pdf - Version 1, February 2025
CTCG Best practice Seasonal Vaccines for sponsor
CTCG Best practice Seasonal Vaccines for Sponsor | pdf - Version 1, January 2025
Fees for clinical trials submitted under CTR 
Fees for clinical trials submitted under CTR | pdf - Version 1.1, July 2025 
Complex Clinical Trials
Complex clinical trials (CCTs) – Questions and answers - Version 1, May 2023Question and Answers document on CCT and CTIS - Version 2.1, May 2026Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials | pdf - Version 1, February 2019
Clinical Trial Safety
Q&A on Safety Addendum - Version 3, December 2025Simplified template of Annual Safety Report - Version 2, October 2025. 
GLP Principles
In order to avoid rejection of clinical trial applications, sponsors should ensure that all pivotal non-clinical safety studies follow the Good Laboratory Practice Recommendation paper provided below. Importantly, all pivotal non-clinical safety studies performed outside OECD or fully MAD adherent countries should fulfil the requirement of a successful GLP inspection (i.e. a full test facility inspection or inspection of the study submitted as part of the dossier) by an EU GLP compliance monitoring authority, within three years before or after the final study report date. This information should be provided in the application dossier, filling in the template table provided below. For additional information about OECD or fully MAD countries, please contact the national contact point of the MS.        
Recommendation paper | pdfTemplate table to provide the requested information | docx
Other Guidance and Q&A Documents
CT-Cure Best Practice Guide and Annex | pdf - Version 1.2, December 2024CTR/IVDR (In Vitro Diagnostic Medical) – Questions and answersAvailable here and hereRecommendations related to contraception and pregnancy testing in clinical trials, version 1.2 | pdf - Version 1.2, March 2024CTCG recommendation to sponsors on managing the impact of the war in Ukraine on clinical trials | pdf - Version 1.2, July 2022


]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7040</link>
                    <guid>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7040</guid>
                    <pubDate>Fri, 22 Sep 2023 14:13:00 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[CTCG Members and Alternates]]></title>
                    <description><![CDATA[CTCG Members and Alternates are nominated by each EU/EEA National Competent Authorities (NCA) and represent the NCA.The Chair and the Vice-Chair of the CTCG are elected amongst the members for a period of three years. Currently CTCG is chaired by Marianne Lunzer, PhD (AGES MEA, Austria) and vice-chaired by Andreas Bonertz, PhD (PEI, Germany)The secretariat is supported by the EMA and an expert from an NCA. The secretariat acts as the contact point for the group.The EMA and the Commission attend the meetings as observers.Representatives from other interested parties and national experts may be consulted and invited to attend the CTCG meetings on an ad hoc basis.
List of CTCG Members and Alternates

Member StateRoleMember NameAT - AustriaChair/MemberMarianne LunzerAT - AustriaAlternateJudith SecklehnerBE - BelgiumMember Anne Lenaers BE - BelgiumAlternate Nele SteensBG - BulgariaMember Ivelina GushlekovaBG - BulgariaAlternate Ivan TodorovCY - CyprusMemberEleni GeorgiadouCY - CyprusAlternateTheognosia PatsaledouCZ - Czech RepublicMember Eva Hrušková Reinová CZ - Czech RepublicAlternateJan NemecekDE - Germany (BfArM)MemberClaudia Riedel DE - Germany (BfArM)AlternateSarah Heil DE - Germany (PEI)MemberSusanne LerchDE - Germany (PEI)Vice-Chair/AlternateAndreas BonertzDK - DenmarkMemberLene Grejs PetersenDK - DenmarkAlternatePernille SterlingEE - EstoniaMemberKeiu HeinlaEE - EstoniaAlternateIngrid KiiskES - SpainMemberJuan Estévez Álamo ES - SpainAlternateLaura Lavin de JuanFI - FinlandMemberMarita Kailajärvi FI - FinlandAlternatePirjo InkiFR - FranceMemberCorinne KigerGR - GreeceMemberLeonidas KlironomosHR - Croatia (HALMED)MemberMaja PuklekHR - Croatia (HALMED)Alternate Ivana Kosier MihalicHR - Croatia (Miz)MemberIvana Matelic HR - Croatia (Miz)  Alternate Nikolina JozancHU - HungaryMemberÁgnes Zita Hajdú HU - HungaryAlternateHuba Eleőd IE - IrelandMemberClaire Temple IE - Ireland   Alternate  Tracy Keane IS - IcelandMemberAgnes Engilráð Scheving IS - IcelandAlternateUnnur IngólfsdóttirIT - ItalyMemberSandra PetragliaIT - ItalyAlternateDiego Alejandro DriLI - LiechtensteinMemberVlasta ZavadovaLT - LithuaniaMemberArūnas Vaitkevičius LT - LithuaniaAlternateEglė Daniulevičiūtė LU - LuxembourgMemberEdwige ChokotéLU - LuxembourgAlternateDounia BouzidLV - LatviaMemberJana MiglinieceLV - LatviaAlternateVita Berzina MT - MaltaMemberJohn Joseph BorgMT - MaltaAlternateBenjamin MicallefNL - NetherlandsMemberMonique AlNL - NetherlandsAlternateJan Willem KleinovinkNO - NorwayMemberIngvild Aaløkken NO - NorwayAlternateIngvild Løberg Tangen PL - PolandMemberEwa Ołdak PL - PolandAlternateAgnieszka DzierwaPT - PortugalMemberJoel PassarinhoPT - PortugalAlternateSusana MarquesRO - RomaniaMemberMirela Vîță RO - RomaniaAlternateSilviu Istrate SE - SwedenMemberGunilla Andrew-Nielsen SE - SwedenAlternateAnn Marie Janson LangSI - SloveniaMemberMaja SkofSI - SloveniaAlternateJurij ŽelSK - SlovakiaMemberJana Grobarčík BallekováSK - SlovakiaAlternateLenka Igazová]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7043</link>
                    <guid>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7043</guid>
                    <pubDate>Thu, 04 Aug 2022 11:13:00 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[FAST-EU Facilitating and Accelerating Strategic Clinical Trials in the EU/EEA
FAST-EU is an initiative by HMA, CTCG and MedEthics EU that enables an accelerated assessment of multinational clinical trials in the European Union. Operating within the EU Clinical Trials Regulation and CTIS, FAST-EU offers sponsors a predictable and efficient pathway for initial clinical trial applications.
The core feature of FAST-EU is a maximum overall timeline of 10 weeks (70 calendar days) from CTIS submission to final conclusion, including sponsor response times. This is achieved through parallel validation and assessment workflows and a strengthened role of the RMS, while maintaining scientific, safety and ethical standards. Ethics Committee opinions are fully integrated across all participating Member States.
Beyond accelerating individual applications, FAST-EU also functions as a structured learning and evidence-generation exercise. The pilot is designed to provide practical insights into the feasibility and challenges of the accelerated assessment model, thereby supporting the future implementation of the EU Biotech Act.
FAST-EU is a voluntary pilot with a planned duration of a year and a limited number of applications per month, so participation cannot be guaranteed.
The following Member States are participating in FAST-EU:
AT, BE, BG, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, HU, IE, IT, LT, LV, NL, NO, PL, PT, RO, SE, SI, SK
Detailed procedural information is provided in the FAST-EU Sponsor Guide.
To enter a trial that is ready for submission in CTIS into FAST-EU , sponsors should express their interest by sending the Expression of Interest Template which can also be found as Annex to the FAST-EU Sponsor Guide via e-mail to FAST-EU@hma.eu. Submission windows are provided in the table below. Expression of Interest should indicate whether CTIS submission would be feasible in the first or second half of the relevant month. A response can be expected within 5 business days.
For Italy and Spain please provide the responsible Ethics Committee. The list of Italian Ethics Committees participating in the FAST-EU project is available on the AIFA website and at the following link. For the Spanish Ethics Committees please see the AEMPS website at the following link (see the section “CEIm adheridos a procedimientos de evaluación acelerada”).

MonthSubmission windowResponse June 20-21 May28 MayJuly22-23 June30 JuneAugust22-23 July30 JulySeptember20-21 August28 AugustOctober22-23 September30 SeptemberNovember22-23 October30 OctoberDecember19-20 November27 November
A total of 103 Expressions of interest have been received from the launch of the project with 23 clinical trials already selected for the accelerated assessment. In response to this high level of interest, and due to the substantial number of applications received, participating Member States agreed to accept more applications than initially planned. This collaborative decision underlines the commitment of the National Competent Authorities involved to keep supporting the project’s fast pace and broad participation. The following Reporting Member States have been selected for FAST EU until now:
AustriaBelgiumCzech RepublicDenmarkEstoniaFinland  France Germany  HungaryIreland ItalyLatviaNorwayNetherlandsPoland  PortugalSloveniaSpain  Sweden   
These selections reflect efforts to distribute workload appropriately while maintaining feasibility across participating Member States. To support an equitable distribution of workload and to broaden Member State participation in the pilot, sponsors are encouraged to select RMS that have not yet been chosen in previous FAST-EU rounds whenever feasible.

]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7860</link>
                    <guid>https://www.hma.eu//about-hma/working-groups/clinical-trials-coordination-group/clinical-trials-coordination-group.html#c7860</guid>
                    <pubDate>Wed, 21 Jan 2026 10:36:12 +0100</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[HMPWG Reports]]></title>
                    <description><![CDATA[Reports from meetings

26-27 February 2026, Limassol (Cyprus): report | pdfAdopted in June 202627 March 2025, Virtual, Warsaw (Poland): report | pdfAdopted in February 202621 November 2024, Virtual, Bonn (Germany): report │ pdfAdopted in March 202525-26 June 2024, Virtual, Bruges (Belgium): report | pdfAdopted in November 202418 October 2023, Virtual, Vienna (Austria): report | pdfAdopted in June 202429-30 March 2023, Uppsala (Sweden): report | pdfAdopted in October 202327-28 October 2022, Rome (Italy): report | pdfAdopted in March 202312-13 May 2022, Paris (France): report | pdfAdopted in October 202210 November 2021, Ljubljana (Slovenia): report | pdfAdopted by written procedure in January 202228 January 2021, Lisbon (Portugal): report | pdfAdopted by written procedure in April 202101-02 September 2020, Bonn (Germany) report | pdfAdopted by written procedure in October 202024-25 October 2019, Bucharest (Romania): report | pdfAdopted by written procedure in December 201923-24 May 2019, Bucharest (Romania): report | pdfAdopted in October 201918-19 Oct 2018, Vienna (Austria): report | pdfAdopted by written procedure in February 201917-18 May 2018, Berlin (Germany): report | pdf5-6 December 2017, Uppsala (Sweden): report | pdf26-27 June 2017, Gozo (Malta): report | pdf10-11 November 2016, Bern (Switzerland): report | pdfAdopted by written procedure in January 201714-15 April 2016, Utrecht (The Netherlands): report | pdfAdopted by written procedure in June 201611-12 November 2015, Utrecht (The Netherlands): report | pdfAdopted by written procedure in January 201628-29 May 2015, Strasbourg (France): report | pdf4-5 December 2014, Rome (Italy): report | pdf5-6 June 2014, Paris (France): report | pdfRevision to Public Report | pdf21-22 November 2013, Bonn (Germany): report | pdf30-31 May 2013, Dublin (Ireland): report | pdf23 October 2012, Gdansk (Poland): report | pdf5-6 June 2012, Copenhagen (Denmark): report | pdf7-8 June 2011, Budapest (Hungary): report | pdf
Other reports
HMPWG Report on the Regulatory Status of Homeopathic Medicinal Products for Human Use in EU/EEA Countries – Update – 2022 | pdfAdopted by consensus at the 36th HMPWG meeting (29-30 March 2023) under the Swedish PresidencyHMPWG Report on the Regulatory Status of Homeopathic Medicinal Products for Human Use in EU And EFTA Countries | pdfAdopted by written procedure in February 2017]]></description>
                    <link>https://www.hma.eu//about-hma/working-groups/homeopathic-medicinal-products-working-group/homeopathic-medicinal-products-working-group-hmpwg.html#c6613</link>
                    <guid>https://www.hma.eu//about-hma/working-groups/homeopathic-medicinal-products-working-group/homeopathic-medicinal-products-working-group-hmpwg.html#c6613</guid>
                    <pubDate>Tue, 24 Oct 2023 11:10:00 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[27 - 28 May 2026, Paphos (Cyprus) - 124th HMA Meeting I Stakeholders information: report | pdf]]></description>
                    <link>https://www.hma.eu//about-hma/meetings/meeting-reports.html#c7896</link>
                    <guid>https://www.hma.eu//about-hma/meetings/meeting-reports.html#c7896</guid>
                    <pubDate>Tue, 09 Jun 2026 13:45:44 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[]]></title>
                    <description><![CDATA[24 February 2026, Virtual (Cyprus) - 123rd HMA Meeting I Stakeholders information: report | pdf]]></description>
                    <link>https://www.hma.eu//about-hma/meetings/meeting-reports.html#c7895</link>
                    <guid>https://www.hma.eu//about-hma/meetings/meeting-reports.html#c7895</guid>
                    <pubDate>Thu, 28 May 2026 09:34:50 +0200</pubDate>
                </item>
            
                <item>
                    <title><![CDATA[2026]]></title>
                    <description><![CDATA[]]></description>
                    <link>https://www.hma.eu//about-hma/meetings/meeting-reports.html#c7894</link>
                    <guid>https://www.hma.eu//about-hma/meetings/meeting-reports.html#c7894</guid>
                    <pubDate>Thu, 28 May 2026 09:34:50 +0200</pubDate>
                </item>
            
        </channel>
    </rss>




    


        



